Lisata subsidiary Marea Therapeutics reports up to 72% triglyceride reduction in Phase 2b trial
Lisata Therapeutics' subsidiary Marea reported that its experimental antibody MAR001 reduced triglycerides by up to 72.2% in a Phase 2b trial, meeting all objectives. The trial involved 235 adults with severe hypertriglyceridemia. MAR001 also reduced remnant cholesterol and showed a safety profile comparable to placebo. Marea has started Part B of the trial and is developing a longer-acting version, MAR005.
How this was made
The 30-second read
Why it matters
The data represent a material clinical milestone that could de‑risk the program and attract partnership or financing opportunities.
Market read
Positive trial results are likely to drive short‑term buying interest in LSTA and may influence the broader lipid‑therapy sector.
What to watch
Regulatory pathway uncertainty and competition from other triglyceride‑lowering agents.
Background
Lisata Therapeutics (NASDAQ:LSTA) announced Phase 2b data for its experimental antibody MAR001, targeting ANGPTL4, showing up to 72.2% triglyceride reduction in severe hypertriglyceridemia patients.
Ticker impact
Lisata Therapeutics subsidiary Marea Therapeutics reported up to 72% triglyceride reduction in a Phase 2b trial, a first‑time disclosure of pivotal data.
likely upward pressure as investors price in the positive trial outcome
Data exceed expectations, meet primary endpoints, and suggest a viable first‑in‑class therapy, prompting buy‑side interest.
Market effects
May boost sentiment for lipid‑metabolism biotech peers and raise interest in ANGPTL4‑targeted therapies.
Limited to US biotech sector; no broader regional effect.
Potentially relevant to global investors tracking novel cardiovascular treatments.
Counterpoint
If Phase 3 fails to replicate efficacy or safety, the current hype could reverse sharply.
Key entities
- companyLisata Therapeutics Inc
US‑listed biotech developing MAR001.
- subsidiaryMarea Therapeutics
Lisata's subsidiary conducting the trial.

